Smarter. Stronger. Together: Optimizing Personalized TNBC Care for Providers and Patients

Register now for this interactive, engaging and conversational webinar to hear about the key areas of consensus and controversy regarding the latest clinical research data on the optimal management of patients with TNBC and how to personalize patient care. After the cancer conversations webinar, view the on-demand webcast, download the associated slideset and listen to the audio podcast for use in your clinic.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome and Introductions

Current Data, Case Discussion, and Strategies for Using PD-1/PD-L1 Inhibitors in TNBC

  • Practice changing new advances in ICI therapy for early-stage TNBC
  • Clinical implications of PD-L1 on therapeutic planning for metastatic TNBC
  • Current and future role of ICI-based therapy in TNBC
  • Toxicity management for patients receiving PD-1/PD-L1 inhibitors

Current Data, Case Discussion, Strategies, and the Future of antibody-drug conjugates (ADCs)

  • Greatest medical need for therapies in the third line and beyond
  • Available data with immediate or near-immediate practice change implications relative to the role of ADCs in TNBC
  • Toxicity management for patients receiving ADCs

BRCA1/2 Mutation, Homologous Recombination Deficiency, and PARP Inhibition

  • Optimal therapy for patients with PD-L1+, BRCA1/2-mutant TNBC
  • Optimal therapy for patients with TNBC harboring somatic BRCA or germline PALB2 mutations
  • Toxicity management for patients receiving PARP inhibitors

Summary, and Audience Question and Answer Session


Date / Time
Event Details


Mark Pegram, MD

Medical Oncology
Stanford University
Palo Alto, California

Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Program Overview
This program will provide expert perspectives on how to optimize and personalize the care of patients with TNBC, including strategies for the optimal selection and sequencing of immune checkpoint inhibitors, antibody-drug conjugates and PARP inhibitors, and managing associated adverse events, as well as considerations for implementing shared decision making and coordinating care among the multidisciplinary team.

Goal Statement
The goal of this activity is to educate oncologists, oncology nurses, pharmacists, physician assistants/physician associates, and other HCPs about recent developments in the care of TNBC to optimally individualize therapy for this patient population.

Target Audience
This program is intended for physicians, nurses, physician assistants/physician associates, pharmacists, and other healthcare professionals who care for patients with TNBC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate available data on the use of immune-based therapies as part of neoadjuvant/adjuvant treatment for early-stage triple-negative breast cancer
  • Plan individualized first-line treatment for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations using antibody–drug conjugates for patients with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Foster collaborative discussions between patients/caregivers and providers on guidelines and recent clinical evidence to guide personalized treatment planning for triple negative breast cancer
  • Implement resources to engage patients in shared decision-making about treatment for triple negative breast cancer
  • Appraise ongoing clinical trials assessing new targeted agents and novel approaches for appropriate patients with triple-negative breast cancer


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Smart Patients. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team."

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-261-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associates Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.